RYZUMVI: Pharmaceutical manufacturers, suppliers, and distributors

Subscribe to access the full database, or Get Started Free
Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Famygen Life Sci	RYZUMVI	phentolamine mesylate	SOLUTION;OPHTHALMIC	217064	NDA	Oyster Point Pharma, Inc.	83368-075-30	6 POUCH in 1 CARTON (83368-075-30) / 5 VIAL, SINGLE-USE in 1 POUCH / .31 mL in 1 VIAL, SINGLE-USE	2024-03-25
Famygen Life Sci	RYZUMVI	phentolamine mesylate	SOLUTION;OPHTHALMIC	217064	NDA	Oyster Point Pharma, Inc.	83368-075-31	1 POUCH in 1 CARTON (83368-075-31) / 5 VIAL, SINGLE-USE in 1 POUCH / .31 mL in 1 VIAL, SINGLE-USE	2024-03-25
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>NDA/ANDA	>Supplier	>Package Code	>Package	>Marketing Start

Last updated: August 1, 2025

Introduction

RYZUMVI (sintilimab injection) is a groundbreaking immunotherapy agent developed by Innovent Biologics and Eli Lilly, primarily used for treating various cancers such as non-small cell lung cancer (NSCLC), gastric cancer, and esophageal squamous cell carcinoma. Approved in China in 2021, RYZUMVI is a PD-1 inhibitor that leverages immune checkpoint blockade to enhance anti-tumor activity. As a biotherapeutic agent, its supply chain involves complex manufacturing, distribution networks, and regulatory considerations. This article examines the key suppliers involved in the production and distribution of RYZUMVI, focusing on biologics manufacturing, raw material sourcing, and global distribution channels.

Manufacturers and Contract Manufacturing Organizations (CMOs)

Innovent Biologics is the primary developer and licensed holder of RYZUMVI. The company’s in-house manufacturing facilities are strategically located in China, enabling a controlled supply chain for domestic distribution. To ensure scalable production, Innovent employs several CMOs specializing in biologics:

Globally Recognized CMOs:
Major international CMOs like Samsung Biologics, Boehringer Ingelheim, and WuXi Biologics are increasingly involved in manufacturing monoclonal antibodies (mAbs) akin to sintilimab. While specific details on RYZUMVI's outsourced manufacturing are proprietary, industry trends suggest that Innovent collaborates with these global CMOs to bolster capacity amid rising demand.
WuXi Biologics:
Based in China, WuXi Biologics is a leader in biologics manufacturing, providing end-to-end services including cell line development, upstream and downstream processing, and fill-finish operations. WuXi's partnership network and manufacturing expertise make it a likely candidate supplier for RYZUMVI’s active substance or final dosage form, especially for Asian markets.
Samsung Biologics:
As a key player in large-scale biologics manufacturing, Samsung offers Cost-Effective, high-capacity bioprocessing facilities in South Korea, serving as a strategic outsourcing partner for innovative therapeutics. Given the global demand for Sintilimab, Samsung's state-of-the-art facilities could supply RYZUMVI to regional or international markets.

Raw Material Suppliers

The manufacturing of monoclonal antibodies like sintilimab depends heavily on high-quality raw materials, including:

Cell Culture Media & Reagents:
Suppliers such as Thermo Fisher Scientific, GE Healthcare (Cytiva), and MilliporeSigma provide specialized media, growth factors, and raw materials essential for cell culture processes.
Bioreactors & Chromatography Resins:
Companies like Cytiva and GE Healthcare supply chromatography resins and filtration materials crucial for downstream processing and purification.
Pharmaceutical-Grade APIs & Buffers:
Raw materials for formulation, including buffers and stabilizers, often originate from global suppliers adhering to GMP standards, with manufacturers like Merck and Thermo Fisher Scientific providing bulk components.

Quality assurance across these raw material suppliers is paramount since biologics manufacturing demands stringent control over purity, potency, and stability parameters to meet regulatory standards [1].

Distribution and Supply Chain Partners

Distribution channels for RYZUMVI depend on regional regulatory approvals and commercial agreements. The pathways include:

Domestic Distribution (China):
Innovent likely partners with a network of logistics providers such as Sinopharm or Shanghai Pharma, which specialize in temperature-controlled logistics for biologics. Cold chain management ensures stability during transit, complying with biosafety standards set by the National Medical Products Administration (NMPA).
International Markets:
As RYZUMVI gains approvals outside China, Eli Lilly assumes a more prominent role in distribution, leveraging its global logistics infrastructure, including partnerships with DHL and FedEx, for international shipments. Regulatory-approved importers and distributors in target markets (e.g., Southeast Asia, Europe, or North America) are essential for market penetration.
Supply Agreements & Stock Management:
Strategic supply agreements with healthcare providers, hospitals, and specialty pharmacies facilitate efficient distribution. Inventory management systems integrated with real-time tracking ensure demand-supply equilibrium and mitigate shortages.

Regulatory and Supply Chain Challenges

The supply chain for RYZUMVI faces unique challenges:

Manufacturing Scalability:
The complexity of biologics production necessitates robust scalability. Capacity expansion hinges on establishing additional manufacturing suites or outsourcing to more CMOs, which can be time-consuming and capital-intensive.
Raw Material Availability:
Global shortages of critical raw materials, especially bioreactor components or purification resins, could impact manufacturing schedules.
Regulatory Compliance:
Ensuring consistent quality across different manufacturing sites necessitates strict adherence to GMP standards. International regulatory requirements also influence supplier qualification.
Cold Chain Logistics:
Maintaining the cold chain throughout distribution is vital for preserving product efficacy, demanding sophisticated logistics infrastructure.

Emerging Trends and Strategic Considerations

With increased competition and generic biosimilar development, securing reliable suppliers and diversifying manufacturing partnerships are vital for continuity. Advancements in cell line engineering, process intensification, and digital monitoring are expected to bolster supply resilience. Collaborations between Innovent, Eli Lilly, and external CMOs offer strategic flexibility to meet global demand.

Furthermore, regional manufacturing hubs in Asia and partnerships with global logistics companies are shaping a resilient supply chain ecosystem for RYZUMVI, improving accessibility and reducing delivery times worldwide.

Key Takeaways

Primary manufacturing involves Innovent Biologics, supported by international CMOs like WuXi Biologics and Samsung Biologics.
Raw materials suppliers include major players such as Thermo Fisher Scientific, GE Healthcare, and MilliporeSigma, ensuring high-quality bioprocessing reagents.
Distribution channels combine domestic logistics providers with global partners to facilitate cold chain management and international shipping.
Supply chain challenges pose risks related to capacity, raw material shortages, and regulatory compliance, necessitating strategic diversification.
Emerging trends focus on process scalability, regional manufacturing hubs, and digital supply chain innovations for enhanced resilience.

FAQs

1. Who are the main manufacturers of RYZUMVI?
Innovent Biologics, in partnership with contract manufacturing organizations such as WuXi Biologics and Samsung Biologics, predominantly produce RYZUMVI, leveraging in-house facilities and outsourced partners.

2. What raw materials are essential for RYZUMVI production?
High-quality cell culture media, chromatography resins, filtration materials, buffers, and stabilizers from suppliers like Thermo Fisher Scientific and GE Healthcare are critical.

3. How is RYZUMVI distributed globally?
In China, local logistics providers manage distribution; internationally, Eli Lilly coordinates with global logistics firms and regional distributors, ensuring cold chain integrity.

4. What are the risks in RYZUMVI’s supply chain?
Capacities of manufacturing sites, raw material shortages, stringent quality controls, and cold chain logistics are key risks that could impact supply continuity.

5. Are there plans to expand RYZUMVI’s manufacturing capacity?
Yes, strategic partnerships with additional CMOs and regional manufacturing hubs are under consideration to meet growing global demand and ensure supply resilience.

References

[1] Innovent Biologics. "Sintilimab (RYZUMVI)." Official Product Documentation, 2022.

Suppliers and packagers for RYZUMVI

RYZUMVI

Suppliers for the Pharmaceutical Drug: RYZUMVI